Texas is currently home to 4849 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Recruiting
This study will enroll participants with myelodysplastic syndromes (MDS) with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have not received treatment with a hypomethylating agent previously. Participants will be randomized to receive either ivosidenib (IVO) alone or azacitidine (AZA) alone. IVO will be administered daily throughout the 28-day treatment cycle and AZA will be administered for the first 7 days of each 28-day cycle. Study visits will be conducted every week during Cy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: University of Texas UT Southwestern Comprehensive Cancer Center, Dallas, Texas
Conditions: Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
Dronabinol as an Adjunct for Reducing Pain
Recruiting
This exploratory, proof-of-concept study is a double-blind (participants and investigators will be blinded), placebo-controlled, randomized, two-arm clinical trial of Marinol \[dronabinol, synthetic Δ9-tetrahydrocannabinol (THC)\] for chronic low back pain (cLBP) with a 2:1 allocation ratio. Up to 75 subjects will be enrolled in this pilot study and randomized to receive doses of THC (up to 30 mg/day), orally, over 8 weeks. This study will be conducted at a single site; it does not include any s... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
02/13/2025
Locations: Michael E Debakey VA Medical Center, Houston, Texas
Conditions: Low Back Pain, Chronic Pain, Back Injuries
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Recruiting
The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the disease. The goal of Phase 2 is to learn if the dose of AD-PluReceptor-NK cells found in Phase 1 in combination with tafasitamab and lymphodepleting chemotherapy can help to control the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Autoimmune Disorders, Systemic Sclerosis
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
Recruiting
This Phase 3, single-arm, multicenter study will evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with low-grade non-muscle invasive bladder cancer (LG-NMIBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Houston Metro Urology (HMU) - Southwest Location, Houston, Texas
Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Exenatide For Reducing the Reinforcing Effects of Cocaine
Recruiting
This study will determine the safety and tolerability of exenatide (Bydureon®) as a pharmacotherapy for cocaine use disorder. An inpatient human laboratory study will be conducted in which the self-administration of cocaine, as well as the subjective and physiological effects of cocaine, are evaluated during maintenance on placebo and exenatide. Although exenatide (Bydureon) is approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes, it has not been approved by t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/13/2025
Locations: Michael E. DeBakey VA Medical Center, Houston, Texas
Conditions: Cocaine Use Disorder
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
Recruiting
To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Chronic Myeloid Leukemia
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
Recruiting
To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/13/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia, HOX Gene
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
Recruiting
This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Prurigo Nodularis (PN).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/13/2025
Locations: Dermresearch, Inc., Austin, Texas
Conditions: Prurigo Nodularis
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Participants With Influenza
Recruiting
The purpose of this study is to evaluate the pre-treatment and single-dose post treatment susceptibility of baloxavir marboxil in participants aged 1 to \<12 years with influenza.
Gender:
ALL
Ages:
Between 1 year and 11 years
Trial Updated:
02/13/2025
Locations: Tekton Research - Beaumont, Beaumont, Texas
Conditions: Influenza
A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms
Recruiting
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered in participants with myeloproliferative neoplasms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Md Anderson Cancer Center, Houston, Texas
Conditions: Myeloproliferative Neoplasms
Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study
Recruiting
To compare the effects of the following types of therapy on knee range of motion when given to patients with chronic knee pain: * A standard steroid injection * Peripheral nerve stimulation (PNS) therapy in combination with a standard steroid injection * PNS therapy in combination with a placebo injection Steroid injections are given directly into the knee joints and are considered to be the standard therapy for chronic knee pain. In this study, the injection will be made of the steroid drugs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Peripheral Nerve Stimulation, Genicular Nerves, Chronic Knee Pain
REBYOTA™ Prospective Registry
Recruiting
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (prim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Ferring Investigational Site, Dallas, Texas
Conditions: Recurrence of Clostridium Difficile Infection